These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 17997804

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM, Ereshefsky L.
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
    Gau SS, Chung CH, Gau CS.
    J Clin Psychopharmacol; 2008 Jun; 28(3):271-8. PubMed ID: 18480683
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
    Laux G, Heeg B, van Hout BA, Mehnert A.
    Pharmacoeconomics; 2005 Jun; 23 Suppl 1():49-61. PubMed ID: 16416761
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
    Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, Culler SD.
    J Med Econ; 2012 Jun; 15(3):531-47. PubMed ID: 22304338
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
    Kilian R, Angermeyer MC.
    Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
    [Abstract] [Full Text] [Related]

  • 14. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
    Zeidler J, Mahlich J, Greiner W, Heres S.
    Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Risperidone. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH, Goa KL.
    Pharmacoeconomics; 1998 Jul; 14(1):97-133. PubMed ID: 10182198
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Schizophrenia: multi-attribute utility theory approach to selection of atypical antipsychotics.
    Bettinger TL, Shuler G, Jones DR, Wilson JP.
    Ann Pharmacother; 2007 Feb; 41(2):201-7. PubMed ID: 17311836
    [Abstract] [Full Text] [Related]

  • 19. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium.
    Lecomte P, De Hert M, van Dijk M, Nuijten M, Nuyts G, Persson U.
    Value Health; 2000 Feb; 3(1):1-11. PubMed ID: 16464176
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M, Sapin C, Beillat M, Robinson P, Treur M.
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.